Phosphodiesterase isozymes: molecular targets for novel antiasthma agents - PubMed (original) (raw)

Review

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

T J Torphy. Am J Respir Crit Care Med. 1998 Feb.

No abstract available

PubMed Disclaimer

Similar articles

• [Cyclic nucleotides phosphodiesterases inhibitors].
  Hagiwara M, Hidaka H. Hagiwara M, et al. Nihon Rinsho. 1991 Sep;49(9):1993-8. Nihon Rinsho. 1991. PMID: 1660084 Japanese. No abstract available.
• [Regulation of the phosphodiesterase activity of cyclic nucleotides (new endogenous regulators)].
  Galoian AA, Gurvits BIa. Galoian AA, et al. Vestn Akad Med Nauk SSSR. 1982;(9):64-9. Vestn Akad Med Nauk SSSR. 1982. PMID: 6293217 Russian. No abstract available.
• Chemical evolution of autotaxin inhibitors.
  Albers HM, Ovaa H. Albers HM, et al. Chem Rev. 2012 May 9;112(5):2593-603. doi: 10.1021/cr2003213. Epub 2012 Feb 15. Chem Rev. 2012. PMID: 22335786 Free PMC article. Review. No abstract available.
• Ginsenosides are potent and selective inhibitors of some calmodulin-dependent phosphodiesterase isozymes.
  Sharma RK, Kalra J. Sharma RK, et al. Biochemistry. 1993 May 18;32(19):4975-8. doi: 10.1021/bi00070a001. Biochemistry. 1993. PMID: 8388250
• Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
  Manganiello V. Manganiello V. Mol Pharmacol. 2003 Jun;63(6):1209-11. doi: 10.1124/mol.63.6.1209. Mol Pharmacol. 2003. PMID: 12761329 Review. No abstract available.

Cited by

• Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension.
  Xing Y, Hou Y, Fan T, Gao R, Feng X, Li B, Pang J, Guo W, Shu T, Li J, Yang J, Mao Q, Luo Y, Qi X, Yang P, Liang C, Zhao H, Chen W, Wang J, Wang C. Xing Y, et al. Acta Pharm Sin B. 2024 Apr;14(4):1726-1741. doi: 10.1016/j.apsb.2024.01.012. Epub 2024 Jan 22. Acta Pharm Sin B. 2024. PMID: 38572107 Free PMC article.
• Once upon a Testis: The Tale of Cyclic Nucleotide Phosphodiesterase in Testicular Cancers.
  Campolo F, Assenza MR, Venneri MA, Barbagallo F. Campolo F, et al. Int J Mol Sci. 2023 Apr 20;24(8):7617. doi: 10.3390/ijms24087617. Int J Mol Sci. 2023. PMID: 37108780 Free PMC article. Review.
• Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis.
  Yang X, Xu Z, Hu S, Shen J. Yang X, et al. Front Pharmacol. 2023 Feb 14;14:1111393. doi: 10.3389/fphar.2023.1111393. eCollection 2023. Front Pharmacol. 2023. PMID: 36865908 Free PMC article. Review.
• Circulating MicroRNAs Expression Profile in Lung Inflammation: A Preliminary Study.
  Mirra D, Cione E, Spaziano G, Esposito R, Sorgenti M, Granato E, Cerqua I, Muraca L, Iovino P, Gallelli L, D'Agostino B. Mirra D, et al. J Clin Med. 2022 Sep 16;11(18):5446. doi: 10.3390/jcm11185446. J Clin Med. 2022. PMID: 36143090 Free PMC article.
• The effects of BRL-50481 on ovalbumin-induced asthmatic lung inflammation exacerbated by co-exposure to Asian sand dust in the murine model.
  Kim HJ, Song JY, Park TI, Choi WS, Kim JH, Kwon OS, Lee JY. Kim HJ, et al. Arch Pharm Res. 2022 Jan;45(1):51-62. doi: 10.1007/s12272-021-01367-x. Epub 2022 Jan 4. Arch Pharm Res. 2022. PMID: 34984603 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database